Eczema Medical Pharmaceutical 
The Dermatology Digest
FEBRUARY 5, 2024
Children and young adults with eczema or allergies or who have difficulty swallowing may have eosinophilic esophagitis, according to a review study in the Canadian Medical Association Journal (CMAJ). Most patients (75%) have at least 1 atopic (allergic) condition, such as food or environmental allergies, asthma, or eczema.
The Dermatology Digest
FEBRUARY 8, 2024
In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Dermatology Digest
MARCH 11, 2024
Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best. Just because they are little doesn’t mean we should be afraid to treat them and make their skin disease better,” she stresses.
The Dermatology Digest
MARCH 10, 2024
Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best. Just because they are little doesn’t mean we should be afraid to treat them and make their skin disease better,” she stresses.
Associated Skin Care Professionals
AUGUST 14, 2023
Osmosis uses a unique combination of active ingredients that focuses on three important factors: our pharmaceutical-grade delivery system, because most aging occurs deep within the skin; our patented products that create real changes in the skin; and our unique inside-out approach that triggers collagen/elastin and plumps the volume of the face.
The Dermatology Digest
MARCH 8, 2024
LEO Pharma recently acquired TMB-001 and other assets from Timber Pharmaceuticals following Timber’s Chapter 11 bankruptcy filing. Mr. Hilberdink: “LEO Pharma is a company that truly aspires to be a leading medical dermatology company that looks at unmet needs in the marketplace, and we see an unmet need in congenital ichthyosis (CI).
The Dermatology Digest
MARCH 11, 2024
Joshua Zeichner, MD, Associate Professor of Dermatology at the Mount Sinai Hospital in New York City, reviews the latest information on prescribing and monitoring isotretinoin for patients with severe nodulocystic acne and provides an update on the potential risks associated with this medication.
Expert insights. Personalized for you.
74 
Let's personalize your content